AstraZeneca's Lynparza Drug Approved in China for Prostate Cancer
24 Juni 2021 - 8:35AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Thursday that its Lynparza drug has been
approved in China to treat advanced prostate cancer.
The pharmaceutical giant said the approval by China's National
Medical Products Administration was based on a subgroup analysis of
the profound phase 3 trial.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 24, 2021 02:23 ET (06:23 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
